Renaissance Capital logo

Beam Therapeutics Priced, Nasdaq: BEAM

Preclinical biotech developing therapies based on single-base gene editing.

Industry: Health Care

First Day Return: +10.3%

Industry: Health Care

We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. The most common class of genetic mutations are errors of a single base, known as point mutations. These point mutations represent approximately 58% of all the known genetic errors associated with disease. Other natural genetic variations of a single base among human populations, revealed by population-level genomic studies, are known to protect against disease. To maximize the impact of these genetic insights, the ability to alter the human genome at the foundational level of genetic information - a single base - is crucial. In the last decade, the field of genetic medicine has reached an inflection point, with groundbreaking advances in gene therapy, cell therapy, oligonucleotides, and, more recently, gene editing. While these technologies represent dramatic advancements for genetic medicines, the ability to edit genes at the single base level has been elusive.
more less
IPO Data
IPO File Date 09/27/2019
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 10.6
Deal Size ($mm) $180
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/05/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $180
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2017
Employees at IPO 87
Website www.beamtx.com

Beam Therapeutics (BEAM) Performance